You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 7,547,680


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,547,680
Title:Benzimidazole derivatives and medical uses thereof
Abstract: The present invention provides benzimidazole derivatives represented by the following formula (I) or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exert an inhibitory activity on sodium-dependent nucleoside transporter 2 and are useful for a disease associated with an abnormality of plasma uric acid level. The compounds of the present invention are useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like. In the formula, n is 1 or 2; R.sup.1 and R.sup.2 are H, a halogen atom, cyano group, optionally substituted alkyl group, optionally substituted aryl group or the like; R.sup.3 is H, a halogen atom, optionally substituted alkyl group or the like; R.sup.4 and R.sup.5 are H, a halogen atom, OH or the like; and R.sup.6 and R.sup.X are H or OH: R.sup.Y is F or OH. ##STR00001##
Inventor(s): Kikuchi; Norihiko (Nagano, JP), Nonaka; Yoshinori (Nagano, JP), Tatani; Kazuya (Nagano, JP), Hiratochi; Masahiro (Nagano, JP), Kuramochi; Yu (Nagano, JP), Isaji; Masayuki (Nagano, JP), Shimizu; Kazuo (Nagano, JP), Miyagi; Takashi (Nagano, JP)
Assignee: Kissei Pharmaceuticals, Co., Ltd. (Nagano, JP)
Application Number:11/473,957
Patent Claims:1. A benzimidazole derivative represented by the general formula: ##STR00178## wherein n represents 1 or 2; R.sup.1 and R.sup.2 independently represents a hydrogen atom, a halogen atom, a cyano group, any of the following substituents (A) to (C) which may have the same or different 1 to 3 groups selected from a substituent group .alpha., any of the following substituents (D) to (G) which may have the same or different 1 to 3 groups selected from a substituent groups .alpha. and .beta., or any of the following substituents (H) to (M); R.sup.3 represents a hydrogen atom, a halogen atom, any of the following substituents (A) to (C) which may have the same or different 1 to 3 groups selected from a substituent group .alpha., or any of the following substituents (H) to (M); (A) a C.sub.1-6 alkyl group; (B) a C.sub.2-6 alkenyl group; (C) a C.sub.2-6 alkynyl group; (D) a C.sub.3-8 cycloalkyl group; (E) a 3 to 10-membered cyclic heterocycloalkyl group; (F) a C.sub.6-10 aryl group; (G) a 5 to 10-membered cyclic heteroaryl group; (H)OR.sup.7; (I) SR.sup.8; (J)NR.sup.9R.sup.10; (K) COOR.sup.11; (L)CONR.sup.12R.sup.13; (M) NHCOR.sup.14 in which R.sup.7 to R.sup.14 independently represents a hydrogen atom, or any of the following substituents (N) to (P) which may have the same or different 1 to 3 groups selected from a substituent group .alpha., or any of the following substituents (Q) to (V) which may have the same or different 1 to 3 groups selected from substituent groups .alpha. and .beta. (N) a C.sub.1-6 alkyl group; (O) a C.sub.2-6 alkenyl group; (P) a C.sub.2-6 alkynyl group; (Q) a C.sub.3-8 cycloalkyl group; (R) a 3 to 10-membered cyclic heterocycloalkyl group; (S) a quaternary salt of a 3 to 10-membered cyclic nitrogen-containing heterocycloalkyl group; (T) a C.sub.6-10 aryl group; (U) a 5 to 10-membered cyclic heteroaryl group; (V) a quaternary salt of a 5 to 10-membered cyclic nitrogen-containing heteroaryl group; R.sup.4 and R.sup.5 independently represent a hydrogen atom, a hydroxy group, a C.sub.1-6 alkyl group or C.sub.1-6 alkoxy group; R.sup.6 and R.sup.x independently represent a hydrogen atom or a hydroxy group; R.sup.Y represents a fluorine atom or a hydroxy group, and with the proviso that at least one of R.sup.1, R.sup.2 and R.sup.3 does not represent a group selected from a hydrogen atom, a halogen atom, a hydroxy group, a C.sub.1-6 alkoxy group, NH.sub.2 and COOH wherein Substituent group .alpha. is: wherein Substituent group .alpha. is: (a) a halogen atom; (b) a cyano group; any of the following substituents (c) to (h) which may have the same or different 1 to 3 groups selected from a substituent group .gamma., or any of the following substituents (i) to (v): (c) a C.sub.3-8 cycloalkyl group; (d) a 3 to 10-membered cyclic heterocycloalkyl group; (e) a quaternary salt of a 3 to 10-membered cyclic nitrogen-containing heterocycloalkyl group; (f) a C.sub.6-10 aryl group; (g) a 5 to 10-membered cyclic heteroaryl group; (h) a quaternary salt of a 5 to 10-membered cyclic nitrogen-containing heteroaryl group; (i) OR.sup.15; (j) SR.sup.16; (k) NR.sup.17R.sup.18; (l) N.sup.+R.sup.DR.sup.ER.sup.F; (m) COOR.sup.19; (o) NHCOR.sup.20; (p) NHC(.dbd.NH)--NH.sub.2; (q) C(.dbd.NH)--NH.sub.2 (which is bound to a nitrogen atom of a nitrogen-containing heterocycloalkyl group); (r) NR.sup.21CONR.sup.22R.sup.23; (s)NR.sup.GSO.sub.2R.sup.H; (t) SO.sub.2R.sup.1(R.sup.1 represents a C.sub.1-6 alkyl group, a C.sub.2-6 alkenylene group or a hydroxyl (C.sub.1-6 alkyl) group); (u) CONR.sup.24R.sup.25; (v) SO.sub.2NR.sup.26R.sup.27 in which R.sup.D-F independently represent any of the following substituents (y1) to (y11) which may have the same or different 1 to 3 groups selected from a substituent group .gamma.; R.sup.15,R.sup.16, R.sup.19-21 and R.sup.G-H independently represent a hydrogen atom, or any of the following substituents (y1) to (y11) which may have the same or different 1 to 3 groups selected from a substituent group .gamma.; R.sup.17, R.sup.18 and R.sup.22 to R.sup.27 independently represent a hydrogen atom, or any of the following substituents (y1) to (y11) which may have the same or different 1 to 3 groups selected from a substituent group .gamma.; or R.sup.17 and R.sup.18, R.sup.22 and R.sup.23, R.sup.24 and R.sup.25, and R.sup.26 and R.sup.27 independently may bind together with the neighboring nitrogen atom to form a 3 to 8-membered aliphatic cyclic amino group (y1) a C.sub.1-6 alkyl group; (y2) a C.sub.2-6 alkenyl group; (y3) a C.sub.2-6 alkynyl group; (y4) a C.sub.3-8 cycloalkyl group; (y5) a 3 to 10-membered cyclic heterocycloalkyl group; (y6) a C.sub.6-10aryl group; (y7) a 5 to 10-membered cyclic heteroaryl group; (y8) a C.sub.3-8 cycloalkyl-C.sub.1-6 alkyl group; (y9) a 3 to 10-membered cyclic heterocycloalkyl-C.sub.1-6 alkyl group; (y10) a C.sub.6-10 aryl-C.sub.1-6 alkyl group; (y11) a 5 to 10-membered cyclic heteroaryl-C.sub.1-6 alkyl group wherein Substituent group .beta. is: any of the following substituents (z1) to (z3) which may have the same or different 1 to 3 groups selected from a substituent group .gamma.; substituent group .gamma.: (z1) a C.sub.1-6 alkyl group; (z2) a C.sub.2-6 alkenyl group; (z3) a C.sub.2-6 alkynyl group wherein Substituent group .gamma. is: (1) a halogen atom; (2) a nitro group; (3) a cyano group; (4)OR.sup.28; (5)SR.sup.29; (6) NR.sup.30R.sup.J wherein R.sup.30 and R.sup.J independently represent a hydrogen atom, a C.sub.1-6 alkyl group, a C.sub.2-6 alkenyl group, a hydroxy(C.sub.1-6 alkyl) group, a C.sub.6-10 aryl-C.sub.1-6 alkyl group or a C.sub.6-10 aryl group; (7) N.sup.+R.sup.KR.sup.LR.sup.M wherein R.sup.K-M independently represent a C.sub.1-6 alkyl group, a C.sub.2-6 alkenyl group, a hydroxy(C.sub.1-6 alkyl) group, a C.sub.6-10 aryl-C.sub.1-6 alkyl group or a C.sub.6-10 aryl group); (8) COR.sup.31; (9) COOR.sup.32; (10) OCOR.sup.33; (11) NHCOR.sup.34; (12) NHC(.dbd.NH)--NH.sub.2; (13) C(.dbd.NH)--NH.sub.2 which is bound to a nitrogen atom of a heterocycloalkyl group (14)NR.sup.35CONR.sup.36R.sup.37; (15)NR.sup.NCOOR.sup.O; (16)CONR.sup.38R.sup.39; (17)SO.sub.2NR.sup.40R.sup.41; (18) a hydroxy(C.sub.2-6 alkyl) group; (19) a 5 to 10-membered cyclic nitrogen-containing heteroaryl group wherein R.sup.28, R.sup.29, R.sup.31-35, R.sup.N and R.sup.O independently represent a hydrogen atom, a C.sub.1-6 alkyl group or a C.sub.6-10 aryl-C.sub.1-6 alkyl group; R.sup.36 to R.sup.41 independently represent a hydrogen atom, or a C.sub.1-6 alkyl group, or R.sup.36 and R.sup.37, R.sup.38 and R.sup.39, and R.sup.40 and R.sup.41 independently may bind together with the neighboring nitrogen atom to form a 3 to 8-membered aliphatic cyclic amino group, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

2. A benzimidazole derivative as claimed in claim 1 wherein n represents 1, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

3. A benzimidazole derivative as claimed in claim 1 or 2 wherein R.sup.Y represents a hydroxy group, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

4. A benzimidazole derivative as claimed in claim 1 wherein R.sup.1 and R.sup.3 independently represent a hydrogen atom, a halogen atom, any of the substituents (A) to (C) which may have the same or different 1 to 3 groups selected from the substituent group .alpha., or any of the substituents (H) to (M), R.sup.2 independently represents a hydrogen atom, a halogen atom, a cyano group, any of the substituents (A) to (C) which may have the same or different 1 to 3 groups selected from the substituent group .alpha., any of the substituents (D) to (G) which may have the same or different 1 to 3 groups selected from the substituent groups .alpha. and .beta., or any of the substituents (H) to (M), or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

5. A benzimidazole derivative as claimed in claims 1, 2 or 4 wherein the substituent: ##STR00179## represents a D-ribosyl group, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

6. A benzimidazole derivative as claimed in claim 3 wherein n represents 1 and both of R.sup.X and R.sup.Y represent a hydroxy group, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

7. A benzimidazole derivative as claimed in claim 6 wherein R.sup.1 represents OR.sup.7 with the proviso that R.sup.7 represents a C.sub.1-6 alkyl group which has a hydroxy group, NR.sup.17R.sup.18 or N.sup.+R.sup.DR.sup.ER.sup.F wherein R.sup.17, R.sup.18 and R.sup.D-F have the same meanings as defined in claim 1 or a hydroxy group; R.sup.2 represents OR.sup.7 with the proviso that R.sup.7 represents a C.sub.1-6 alkyl group which has a hydroxy group, NR.sup.17R.sup.18 or N.sup.30R.sup.DR.sup.ER.sup.F wherein R.sup.17, R.sup.18 and R.sup.D-F have the same meanings as defined in claim 1, a hydroxy group, or a C.sub.6-10 aryl group which may have a hydroxy group or OR.sup.15, wherein R.sup.15 has the same meaning as defined in claim 1, R.sup.3, R.sup.4 and R.sup.5 represent a hydrogen atom, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

8. A pharmaceutical composition comprising as an active ingredient a benzimidazole derivative as claimed in claim 1 or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

9. A method for the treatment of a disease associated with an abnormality of plasma uric acid level comprising administering a pharmaceutical composition as claimed in claim 8 to a person having said disease.

10. The method as claimed in claim 9 wherein the disease associated with an abnormality of plasma uric acid level is a disease selected from gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy and acute uric acid nephropathy.

11. The method as claimed in claim 9 wherein the disease associated with an abnormality of plasma uric acid level is gout.

12. The method as claimed in claim 9 wherein the disease associated with an abnormality of plasma uric acid level is hyperuricemia.

13. A pharmaceutical composition as claimed in claim 8 comprising in combination as an active ingredient at least one agent selected from the group consisting of colchicine, a nonsteroidal anti-inflammatory agent, an adrenocortical steroid, a uric acid synthesis inhibitor, a uricosuric drug, a urinary alkalinizer and a uric acid oxidase.

14. A pharmaceutical composition as claimed in claim 13 wherein the nonsteroidal anti-inflammatory agent is indometacin, naproxen, fenbufen, pranoprofen, oxaprozin, ketoprofen, etoricoxib or tenoxicam; the uric acid synthesis inhibitor is allopurmnol, oxypurinol, febuxostat or Y-700; the uricosuric drug is probenecid, bucolome or benzbromarone; the urinary alkalinizer is sodium hydrogen carbonate, potassium citrate or sodium citrate; the uric acid oxidase is rasburicase, uricase PEG-20, a recombinant uric acid oxidase (uricase).

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.